Wang CH, et al. - Researchers determined the role of prenylated Rab acceptor 1 domain family member 2 (PRAF2), a novel oncogene, in hepatocellular carcinoma (HCC). They used quantitative reverse transcription-polymerase chain reaction and Western blot to examine PRAF2 mRNA and protein expressions, respectively, in fresh tissues. These were also examined in 518 paraffin-embedded HCC samples by immunohistochemistry. They used the Student’s t-test, Kaplan–Meier test, and multivariate Cox regression analysis to determine the correlation of PRAF2 expression and clinical outcomes. They found increased PRAF2 in HCC. Furthermore, PRAF2 was found to be a novel unfavorable biomarker for prognostic prediction in patients with HCC.